Zaderej Karen L. purchased $52K of EYPT

Zaderej Karen L. purchased 10,600 shares of EyePoint, Inc. (EYPT) at $4.93 on 2026-08-18.

Original reporting
SEC EDGAR · Zaderej Karen L.
Published Aug 18, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EYPT
Bullish
medium confidence
Mentioned
$EYPT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EYPTBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase of 10,600 shares at $4.93 on 2026-08-18, with holdings after the trade of 49,100 shares.

02

Market read

Traders may treat the Form 4 as a small sentiment input, but it does not introduce new operating or financial information.

03

What to watch

The filing notes no 10b5-1 plan, but it still does not provide context on motivation, timing constraints, or whether the director has other concurrent transactions.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18, same day as the reported purchase date

Background

The article is an SEC Form 4 insider transaction disclosure for EyePoint, Inc.

Company-level read

Ticker impact

$EYPTBullishMedium confidence
Context

EyePoint director Zaderej Karen L. bought 10,600 shares on 2026-08-18 at $4.93, totaling $52,258, per Form 4.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically small versus market-moving events.

Evidence & confidence

The filing is a primary-source Form 4 and the buyer is a director, but the transaction size is relatively small and there is no accompanying company-specific news (no guidance, trial, contract, or regulatory action).

Market effects

No clear sector read-through; this is a single-company insider transaction without new clinical or regulatory information.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine (tax planning, diversification, or pre-existing intent) and may not reflect near-term operational improvements.

Key entities

  • EyePoint, Inc.

    Company whose director insider purchase is disclosed on Form 4.

  • Zaderej Karen L.

    Director who purchased 10,600 shares for $52,258 on 2026-08-18.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EYPTHighAI 8/10

EyePoint Pharma Earnings Call: DME Focus After Wet AMD Setback

EyePoint Pharma reported Q3 earnings, highlighting a setback in wet AMD trials and a 53% workforce reduction. Despite this, the company remains focused on DURAVYU for diabetic macular edema (DME), citing positive VERONA study results. EyePoint has $118M in cash, expected to last into late Q3 2027, and plans to report DME trial results in early Q4 2027.

$EYPTHighAI 8/10

Stifel cuts EyePoint stock price target on trial setbacks

Stifel reduced its price target for EyePoint Inc. (EYPT) to $5.00 from $6.00, citing clinical trial setbacks. The company's stock is near its 52-week low, down 97% over the past year. EyePoint reported a larger-than-expected loss but exceeded revenue expectations in Q3 2026. The company has $118 million in cash and is focusing on its Duravyu treatment for diabetic macular edema.

$EYPTMed

EyePoint Misses As Twin Wet AMD Failures Leave A Shrunken Company Racing Its Cash Runway To A Binary DME Readout

EyePoint reported a Q3 loss of $1.07 per share, missing estimates, with revenue of $0.76M. The company halted its wet AMD program after trial failures, focusing on DME. Cash reserves fell to $118M, and the company plans workforce reductions. DME trial results are expected in Q4 2027, but financing may be needed before then. Shares have dropped 97% since August.

$EYPTMedAI 8/10

EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments

EyePoint, Inc. (EYPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments – Organizational focus on DURAVYU TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – – DURAVYU DME program supported by the posit